Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR
Why:Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the investing public.
So What: If you purchased Capricor securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next:To join the prospective class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
What is this about: On July 27, 2026, Reuters published an article entitled "FDA staff flags data concerns about Capricor's therapy; shares plunge." The article stated that FDA "staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics' cell therapy for a heart condition related to Duchenne muscular dystrophy, dragging the company's shares 65% lower in early trading." Further, the "briefing documents, released on Monday, mention the effectiveness and risk-benefit profile of the experimental therapy, deramiocel, to be discussed at the FDA's external advisers' meeting on Wednesday."
